Mirtazapine orally disintegrating tablets versus venlafaxine extended release: A double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 75-78

  Benkert, Otto ^a,g   Szegedi, Armin ^b,c   Philipp, Michael ^d   Kohnen, Ralf ^e   Heinrich, Claus ^e   Heukels, Anja ^f   Van Der Vegte Senden, Monique ^f   Baker, Ross A ^c   Simmons, John H ^c   Schutte, Albert Jan ^c  

^a PAS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Bezirkskrankenhaus Landshut   (Germany)

^e IMEREM GmbH   (Germany)

^f NV ORGANON   (Netherlands)

^g NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE; REMERGIL SOLTAB; TREVILOR RETARD; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SLEEP; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; SUSTAINED DRUG RELEASE; TABLET DISINTEGRATION; TREATMENT RESPONSE; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIANSERIN; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; TABLETS; TIME FACTORS;

EID: 31544450244     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000194622.99986.d6     Document Type: Article

References (20)

1. Montgomery SA. Fast-onset antidepressants. Int Clin Psychopharmacol. 1997;12(suppl 3):S1-S5.
2. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry. 2001;62(suppl 15):S12-S17.
3. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10(suppl 4):S19-S23.
4. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol. 2003;13:57-66.
5. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59:306-312.
6. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol. 1999;14:329-337.
7. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61:656-663.
8. Montgomery S, Schutte A, Reimitz P. Mirtazapine and onset of action of antidepressant activity. Int J Neuropsychopharmacol. 2000; 3(suppl 1):249.
9. Quitkin F. Onset of action with mirtazapine appears to be more rapid than SSRIs. Int J Neuropsychopharmacol. 2000;3(suppl 1):245.
10. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23:358-364.
11. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother. 1995;29:387-395.
12. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995;56:450-458.
13. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther. 1998;20:517-526.
14. Benkert O, Grunder G, Wetzel H, et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res. 1996;30:441-451.
15. van den Heuvel MW, Kleijn HJ, Peeters PAM. Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers. Clin Drug Invest. 2001;21:437-442.
16. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355:911-918.
17. Thase ME. Methodology to measure onset of action. J Clin Psychiatry. 2001;62(suppl 15):18-21.
18. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66:148-158.
19. Schatzberg AF. Pharmacologic mechanisms of antidepressant action. In: Keller MB, Pinder RM, chairs. The role of mirtazapine in the pharmacotherapy of depression. J Clin Psychiatry. 2000;61:609-616.
20. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl. 1997;391:31-37.